Liquidia Corporation

NasdaqCM:LQDA Stock Report

Market Cap: US$2.3b

Liquidia Valuation

Is LQDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LQDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$135.81
Fair Value
79.9% undervalued intrinsic discount
9
Number of Analysts

Below Fair Value: LQDA ($27.35) is trading below our estimate of fair value ($135.81)

Significantly Below Fair Value: LQDA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LQDA?

Key metric: As LQDA barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for LQDA. This is calculated by dividing LQDA's market cap by their current book value.
What is LQDA's PB Ratio?
PB Ratio155x
BookUS$15.19m
Market CapUS$2.33b

Price to Book Ratio vs Peers

How does LQDA's PB Ratio compare to its peers?

The above table shows the PB ratio for LQDA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.6x
BLTE Belite Bio
13.9x67.78%US$2.0b
SUPN Supernus Pharmaceuticals
2.2xn/aUS$2.4b
OCUL Ocular Therapeutix
6.8x29.89%US$2.1b
OGN Organon
3.3x14.52%US$2.4b
LQDA Liquidia
155x62.73%US$2.3b

Price-To-Book vs Peers: LQDA is expensive based on its Price-To-Book Ratio (155x) compared to the peer average (6.6x).

Price to Book Ratio vs Industry

How does LQDA's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

14 CompaniesPrice / BookEstimated GrowthMarket Cap
VYNE VYNE Therapeutics
0.2x-27.64%US$8.33m
SPRC SciSparc
0.3xn/aUS$2.41m
UPC Universe Pharmaceuticals
0.04xn/aUS$2.01m
PTPI Petros Pharmaceuticals
0.3xn/aUS$1.25m
LQDA 155.0xIndustry Avg. 1.9xNo. of Companies22PB01.22.43.64.86+
14 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: LQDA is expensive based on its Price-To-Book Ratio (155x) compared to the US Pharmaceuticals industry average (2x).

Price to Book Ratio vs Fair Ratio

What is LQDA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LQDA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio155x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate LQDA's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LQDA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$27.35
US$36.67
+34.06%
35.09%US$54.00US$6.00n/a9
Aug ’26US$17.68
US$30.30
+71.38%
32.30%US$41.00US$6.00n/a10
Jul ’26US$12.00
US$30.30
+152.50%
32.30%US$41.00US$6.00n/a10
Jun ’26US$14.92
US$30.00
+101.07%
26.71%US$41.00US$13.00n/a10
May ’26US$13.98
US$26.78
+91.54%
19.59%US$35.00US$20.00n/a9
Apr ’26US$14.51
US$26.78
+84.55%
19.59%US$35.00US$20.00n/a9
Mar ’26US$15.49
US$25.33
+63.55%
17.94%US$31.00US$19.00n/a9
Feb ’26US$14.23
US$25.00
+75.69%
20.04%US$31.00US$17.00n/a9
Jan ’26US$11.76
US$25.30
+115.14%
19.12%US$31.00US$17.00n/a10
Dec ’25US$11.55
US$25.44
+120.30%
18.16%US$31.00US$17.00n/a9
Nov ’25US$10.98
US$25.33
+130.72%
17.75%US$30.00US$17.00n/a9
Oct ’25US$10.22
US$24.00
+134.83%
17.68%US$29.00US$17.00n/a7
Sep ’25US$9.51
US$24.00
+152.37%
17.68%US$29.00US$17.00n/a7
Aug ’25US$11.59
US$27.67
+138.71%
11.56%US$32.00US$23.00US$17.686
Jul ’25US$12.04
US$24.14
+100.52%
37.80%US$32.00US$3.00US$12.007
Jun ’25US$12.87
US$24.14
+87.59%
37.80%US$32.00US$3.00US$14.927
May ’25US$13.17
US$25.14
+90.91%
36.79%US$32.00US$3.00US$13.987
Apr ’25US$14.92
US$23.86
+59.90%
38.77%US$32.00US$3.00US$14.517
Mar ’25US$14.52
US$21.14
+45.61%
42.86%US$30.00US$3.00US$15.497
Feb ’25US$13.60
US$20.86
+53.36%
44.20%US$30.00US$3.00US$14.237
Jan ’25US$12.03
US$18.29
+52.00%
46.38%US$30.00US$3.00US$11.767
Dec ’24US$7.27
US$14.00
+92.57%
34.15%US$18.00US$3.00US$11.557
Nov ’24US$6.59
US$14.00
+112.44%
34.15%US$18.00US$3.00US$10.987
Oct ’24US$6.34
US$14.00
+120.82%
34.15%US$18.00US$3.00US$10.227
Sep ’24US$7.00
US$14.00
+100.00%
34.15%US$18.00US$3.00US$9.517
Aug ’24US$7.80
US$14.00
+79.49%
34.15%US$18.00US$3.00US$11.597
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
US$36.67
Fair Value
25.4% undervalued intrinsic discount
9
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/20 12:57
End of Day Share Price 2025/08/20 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Liquidia Corporation is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Julian HarrisonBTIG
Andrew FeinH.C. Wainwright & Co.